Rimegepant: A New Hope for Episodic Migraine Sufferers

Research Summary

A recent study published in the journal Cephalalgia explores the effectiveness of rimegepant, a 75 mg orally disintegrating tablet taken every other day, for preventing episodic migraines in adults who previously experienced inadequate responses to traditional oral preventive medications. This phase 4 trial involved 652 participants, who initially underwent a 28-day observation phase followed by a 12-week double-blind treatment period, comparing rimegepant to a placebo. Results showed that rimegepant significantly reduced monthly migraine days by an average of 2.1 days compared to the placebo's 0.5 days. Additionally, key secondary endpoints, including improvements in quality of life, also favored rimegepant. The drug was well tolerated, showing a safety profile similar to placebo, suggesting it as a promising option for those with limited success using conventional treatments.

Study Details

📄 Title: A phase 4, randomized, double-blind, placebo-controlled trial evaluating the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications.

👥 Research Team: Pozo-Rosich P et al.

📚 Published In: Cephalalgia

📅 Publication Date: 2025 Nov

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.